Rapt Therapeutics Stock Analysis

RAPT Stock  USD 8.93  0.53  6.31%   
RAPT Therapeutics is undervalued with Real Value of 17.03 and Target Price of 41.67. The main objective of RAPT Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what RAPT Therapeutics is worth, separate from its market price. There are two main types of RAPT Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect RAPT Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of RAPT Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The RAPT Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. RAPT Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. RAPT Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and RAPT Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

RAPT Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.99. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. RAPT Therapeutics recorded a loss per share of 3.05. The entity had not issued any dividends in recent years. The firm had 21:1 split on the December 14, 2010. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Rapt Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 88 people. To find out more about RAPT Therapeutics contact Brian MD at 650 489 9000 or learn more at https://www.rapt.com.

RAPT Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. RAPT Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding RAPT Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
RAPT Therapeutics generated a negative expected return over the last 90 days
RAPT Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (116.8 M) with profit before overhead, payroll, taxes, and interest of 1.53 M.
RAPT Therapeutics currently holds about 207.34 M in cash with (97.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: What Makes RAPT Therapeutics an Investment Choice

RAPT Therapeutics Upcoming and Recent Events

Earnings reports are used by RAPT Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to RAPT Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
12th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

RAPT Largest EPS Surprises

Earnings surprises can significantly impact RAPT Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-03-11
2020-12-31-0.59-0.520.0711 
2020-08-13
2020-06-30-0.58-0.510.0712 
2023-05-11
2023-03-31-0.68-0.76-0.0811 
View All Earnings Estimates

RAPT Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as RAPT Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading RAPT Therapeutics backward and forwards among themselves. RAPT Therapeutics' institutional investor refers to the entity that pools money to purchase RAPT Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Braidwell Lp2023-09-30
1.1 M
Morgan Stanley - Brokerage Accounts2023-12-31
M
Samlyn Capital, Llc2023-12-31
711.5 K
Geode Capital Management, Llc2023-12-31
669.3 K
Euclidean Capital Llc2023-12-31
657.9 K
Alphabet Inc2023-12-31
540.3 K
Timessquare Capital Management, Llc2023-12-31
504.3 K
Cormorant Asset Management, Llc2023-12-31
496.8 K
Dimensional Fund Advisors, Inc.2023-12-31
488.3 K
Fmr Inc2023-12-31
3.8 M
T. Rowe Price Associates, Inc.2023-12-31
3.4 M
Note, although RAPT Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

RAPT Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 292.3 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate RAPT Therapeutics's market, we take the total number of its shares issued and multiply it by RAPT Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

RAPT Profitablity

RAPT Therapeutics' profitability indicators refer to fundamental financial ratios that showcase RAPT Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, RAPT Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, RAPT Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of RAPT Therapeutics' profitability requires more research than a typical breakdown of RAPT Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2024
Return On Capital Employed(0.84)(0.88)
Return On Assets(0.67)(0.71)
Return On Equity(0.79)(0.83)

Management Efficiency

RAPT Therapeutics has return on total asset (ROA) of (0.3613) % which means that it has lost $0.3613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5956) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.88 in 2024. Return On Assets is likely to drop to -0.71 in 2024. Total Current Liabilities is likely to drop to about 11.7 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 151.1 M in 2024
Last ReportedProjected for 2024
Price Book Value Ratio 6.48  6.80 
Enterprise Value Multiple(7.39)(7.75)
Price Fair Value 6.48  6.80 
The analysis of RAPT Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze RAPT Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of RAPT Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.467

Technical Drivers

As of the 28th of March, RAPT Therapeutics holds the Market Risk Adjusted Performance of (0.06), mean deviation of 4.66, and Variance of 132.46. Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of RAPT Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the entity will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for RAPT Therapeutics, which can be compared to its competitors. Please check RAPT Therapeutics market risk adjusted performance and treynor ratio to decide if RAPT Therapeutics is priced more or less accurately, providing market reflects its current price of 8.93 per share. Given that RAPT Therapeutics has information ratio of (0.04), we recommend you to check out RAPT Therapeutics's recent market performance to make sure the company can sustain itself at some point in the future.

RAPT Therapeutics Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. RAPT Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for RAPT Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

RAPT Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RAPT Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on RAPT Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RAPT Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

RAPT Therapeutics Predictive Daily Indicators

RAPT Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of RAPT Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

RAPT Therapeutics Corporate Filings

8K
7th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
22nd of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
20th of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
14th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
13th of February 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
9th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
F4
1st of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
26th of January 2024
An amended filing to the original Schedule 13G
ViewVerify

RAPT Therapeutics Forecast Models

RAPT Therapeutics' time-series forecasting models are one of many RAPT Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary RAPT Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About RAPT Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how RAPT Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling RAPT shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as RAPT Therapeutics. By using and applying RAPT Stock analysis, traders can create a robust methodology for identifying RAPT entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin(63.14)(59.98)
Operating Profit Margin(64.61)(61.38)
Net Loss(61.67)(58.58)
Gross Profit Margin(0.96)(0.92)

Current RAPT Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. RAPT analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. RAPT analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
41.67Buy12Odds
RAPT Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most RAPT analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand RAPT stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of RAPT Therapeutics, talking to its executives and customers, or listening to RAPT conference calls.
RAPT Analyst Advice Details

RAPT Stock Analysis Indicators

RAPT Therapeutics stock analysis indicators help investors evaluate how RAPT Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading RAPT Therapeutics shares will generate the highest return on investment. By understating and applying RAPT Therapeutics stock analysis, traders can identify RAPT Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow38.9 M
Common Stock Shares Outstanding38.3 M
Total Stockholder Equity147 M
Property Plant And Equipment Net7.7 M
Cash And Short Term Investments158.9 M
Cash47.5 M
Accounts Payable5.2 M
Net Debt-40.6 M
50 Day M A16.521
Total Current Liabilities21.8 M
Other Operating Expenses127.1 M
Non Current Assets Total11.5 M
Non Currrent Assets Other3.9 M
Stock Based Compensation17.1 M
When determining whether RAPT Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if RAPT Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Rapt Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Rapt Therapeutics Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for RAPT Stock analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is RAPT Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RAPT Therapeutics. If investors know RAPT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RAPT Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.36)
Return On Equity
(0.60)
The market value of RAPT Therapeutics is measured differently than its book value, which is the value of RAPT that is recorded on the company's balance sheet. Investors also form their own opinion of RAPT Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is RAPT Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RAPT Therapeutics' market value can be influenced by many factors that don't directly affect RAPT Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between RAPT Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if RAPT Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RAPT Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.